“We know that certain probiotic strains support immune health and may improve health-related quality of life during upper respiratory infections. This study assessed how probiotic supplementation affects duration of symptoms, severity of symptoms, and the impact of symptoms on daily life, when infected,” explained Tracey J. Smith, adjunct professor, who led the study at the University of Medicine and Dentistry of New Jersey.
198 college students were randomized to receive either placebo or a powder blend containing Chr. Hansen’s probiotic strains BB-12 and LGG for 12 weeks. The median duration of upper respiratory infections was significantly shorter by two days (four days versus six days), and median severity score was significantly lower by 34% with probiotics versus placebo.
For further information: www.chr-hansen.com